Preferred Label : Zotizalkib;
NCIt synonyms : ALK Inhibitor TPX-0131;
NCIt definition : An orally available, compact macrocyclic structure-based inhibitor of the receptor
tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential antineoplastic
activity. Upon oral administration, zotizalkib binds within the ATP binding boundary
and inhibits ALK wild-type tyrosine kinase, ALK fusion proteins and numerous ALK point
mutations, including acquired resistance mutations, such as the solvent front mutation
(SFM) G1202R and compound mutations L1196M/G1202R, L1198F/G1202R, L1196M/L1198F, and
C1156Y/G1202R. Inhibition of ALK leads to the disruption of ALK-mediated signaling
and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the
insulin receptor superfamily and plays an important role in nervous system development.
ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene
rearrangements are associated with a variety of tumor cell types. Compared to other
ALK inhibitors, zotizalkib is able to inhibit ALK resistance mutations associated
with acquired resistance to other ALK inhibitors.;
UNII : 5BKJ4Z6RBU;
CAS number : 2648641-36-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2648641-36-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : TPX-0131; TPX 0131;
NCI Metathesaurus CUI : CL1663039;
Origin ID : C180420;
UMLS CUI : C5556353;
Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
